- Home
- SRTS vs DXR Comparison
SRTS vs DXR Comparison
Compare SRTS & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRTS | DXR |
|---|---|---|
| Founded | 2010 | 1970 |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.5M | 71.4M |
| IPO Year | 2016 | 1995 |
Fundamental Metrics
Financial Performance| Metric | SRTS | DXR |
|---|---|---|
| Price | $4.20 | $9.63 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.67 | N/A |
| AVG Volume (30 Days) | ★ 48.8K | 7.0K |
| Earning Date | 05-14-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,482,000.00 | $1,446,345.00 |
| Revenue This Year | $2.00 | $44,935.22 |
| Revenue Next Year | $34.23 | $74.79 |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.03 | $7.10 |
| 52 Week High | $5.92 | $14.76 |
Technical Indicators
Market Signals| Indicator | SRTS | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 53.61 | 22.63 |
| Support Level | $4.15 | $8.45 |
| Resistance Level | $4.80 | $9.88 |
| Average True Range (ATR) | 0.24 | 0.43 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 60.76 | 3.56 |
Price Performance
Historical ComparisonAbout SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.